Search

Your search keyword '"Jemmolo RM"' showing total 23 results
Start Over Author "Jemmolo RM"
23 results on '"Jemmolo RM"'

1. The monoethylglycinexylidide test for grading of liver cirrhosis

Author

Jemmolo Rm, Mario Strazzabosco, Lajos Okolicsanyi, F. Casagrande, Flavio Lirussi, Gianna Toffolo, Paleari D, Luca Fabris, Claudio Cobelli, S. Viaggi, and Rigon M

Subjects
medicine.medical_specialty, Cirrhosis, Optimal sampling, Hepatology, medicine.diagnostic_test, business.industry, Gastroenterology, Diagnostic accuracy, Serum concentration, medicine.disease, Surgery, Pharmacokinetics, Disease severity, Internal medicine, medicine, Pharmacology (medical), Liver function, Liver function tests, business
Abstract

Background: Monoethylglycinexylidide (MEGX) formation following lignocaine injection has recently been proposed as a simple dynamic liver function test based on a single measurement of its serum concentration. Aim: To determine the optimal sampling time for MEGX determination. Methods: A modelling analysis of lignocaine and MEGX kinetics was performed in seven normals and in four patients with compensated liver cirrhosis; a similar study was performed in 74 cirrhotic patients, divided into two groups according to disease severity (Pugh score). Results: Only the MEGX fractional formation rate (kf) and formation delay (τ) were significantly altered in cirrhotic patients compared to normals: kf = 0.15 ± 0.03 vs. 0.32 ± 0.10 min−1 (mean ± s.d.); τ = 7.7 ± 2.0 vs. 3.9 ± 2.9 min−1. A good correlation was found between kf and late (r = 0.82) but not early (r = 0.63) serum MEGX formation, suggesting that late measurements for the clinical MEGX test are preferred. In the second part of our investigation, by discriminant analysis of MEGX test data for 74 cirrhotic patients, the late MEGX concentrations gave the best discrimination between the two classes. In particular, the 60 min MEGX concentration showed the best diagnostic accuracy (81%), sensitivity (75%) and specificity (84%). The association of this with other MEGX parameters, either singly or derived from the whole curve measurements, did not improve the performance of the method. Conclusion: The MEGX test, based on a single determination 60 min after lignocaine injection, may be regarded as a simple and sensitive quantitative liver function test.

Published
1999
Full Text
View/download PDF

2. The monoethylglycinexylidide test for grading of liver cirrhosis

Author

Fabris, L, Jemmolo, RM, Toffolo, G, Paleari, D, Viaggi, S, Rigon, M, Casagrande, F, Lirussi, F, STRAZZABOSCO, MARIO, Cobelli, C, Okolicsanyi, L., Fabris, L, Jemmolo, R, Toffolo, G, Paleari, D, Viaggi, S, Rigon, M, Casagrande, F, Lirussi, F, Strazzabosco, M, Cobelli, C, and Okolicsanyi, L

Subjects
Adult, Liver Cirrhosis, Male, cirrhosis, Discriminant Analysis, Lidocaine, Middle Aged, Models, Biological, Sensitivity and Specificity, Liver Function Tests, MED/12 - GASTROENTEROLOGIA, liver damage, Monoethylglycinexylidide, Humans, Female, cirrhosis, bile ducts, Monoethylglycinexylidide (MEGX)
Abstract

BACKGROUND: Monoethylglycinexylidide (MEGX) formation following lignocaine injection has recently been proposed as a simple dynamic liver function test based on a single measurement of its serum concentration. AIM: To determine the optimal sampling time for MEGX determination. METHODS: A modelling analysis of lignocaine and MEGX kinetics was performed in seven normals and in four patients with compensated liver cirrhosis; a similar study was performed in 74 cirrhotic patients, divided into two groups according to disease severity (Pugh score). RESULTS: Only the MEGX fractional formation rate (kf) and formation delay (tau) were significantly altered in cirrhotic patients compared to normals: kf = 0.15 +/- 0.03 vs. 0.32 +/- 0.10 min-1 (mean +/- s.d.); tau = 7.7 +/- 2.0 vs. 3.9 +/- 2.9 min-1. A good correlation was found between kf and late (r = 0.82) but not early (r = 0.63) serum MEGX formation, suggesting that late measurements for the clinical MEGX test are preferred. In the second part of our investigation, by discriminant analysis of MEGX test data for 74 cirrhotic patients, the late MEGX concentrations gave the best discrimination between the two classes. In particular, the 60 min MEGX concentration showed the best diagnostic accuracy (81%), sensitivity (75%) and specificity (84%). The association of this with other MEGX parameters, either singly or derived from the whole curve measurements, did not improve the performance of the method. CONCLUSION: The MEGX test, based on a single determination 60 min after lignocaine injection, may be regarded as a simple and sensitive quantitative liver function test

Published
1999

3. Qualità di vita del paziente con cirrosi: effetto del trapianto di fegato

Author

Burra P, De Bona M, Jemmolo RM, Boccagli P, Tedeschi U, Gerunda G, Fagiuoli S, Ruolo GP, Naccarato R, Burra, P, De Bona, M, Jemmolo, R, Boccagli, P, Tedeschi, U, Gerunda, G, Fagiuoli, S, Ruolo, G, and Naccarato, R

Subjects
Qualità di vita, cirrosi, trapianto di fegato
Published
1997

5. ricorrenza di infezione da HCV e qualità di vita dopo trapianto di fegat

Author

De Bona M, Burra P, Ponton P, Jemmolo RM, Destro C, Boccagni P, Buda A, Targhetta S, Fagiuoli S, Rupolo GP, Naccarato R, De Bona, M, Burra, P, Ponton, P, Jemmolo, R, Destro, C, Boccagni, P, Buda, A, Targhetta, S, Fagiuoli, S, Rupolo, G, and Naccarato, R

Subjects
infezione da HCV qualità di vita trapianto di fegato
Published
1997

6. Liver transplantation in Italy: Preliminary 10-year report

Author

Fagiuoli, S., Leandro, G., Bellati, G., Gasbarrini, A., Rapaccini, Gl, Pompili, M., Rendina, M., Denotariis, S., Francavilla, A., Gasbarrini, G., Ideo, G., Naccarato, R., Agnes, S., Castagneto, M., Angeli, P., Angelico, M., Ascione, A., Calise, F., Bertocchi, M., Dardano, G., Borzio, M., Budillon, G., Burra, F., Farinati, F., Cadeo, Gp, Camisasca, M., Podda, M., Paolo, S., Cavallari, A., Mazziotti, A., Casciani, Cu, Tisone, G., Cillo, U., Damico, D., Colombo, M., Donato, F., Conoscitore, P., Coppolecchia, P., Dessanti, A., Fassati, Lr, Lucianetti, A., Rossi, G., Forti, D., Belli, L., Rondinara, Gf, Gaeta, G., Piccinino, F., Gerunda, G., Faccioli, Am, Gridelli, B., Guariso, G., Zancan, L., Gullini, F., Boccia, S., Jemmolo, Rm, Marcellini, M., Marzano, Ma, Marzio, L., Mazzaferro, V., Regalia, E., Morelli, Mc, Pagliaro, L., Palazzo, U., Piras, MR, Ricci, Gl, Salmi, A., Sama, C., Sangiovanni, A., Salizzoni, M., Marzano, A., Smedile, A., Rizzetto, M., Solinas, A., Spina, Gp, Stefanini, Gf, PIETRO ANDREONE, Villa, E., and Zignego, L.

Subjects
Settore MED/12 - Gastroenterologia, liver transplantation, liver disease, rejection
Published
1996

10. Recidiva di epatite da virus C dopo trapianto di fegato: Esperienza di un centro Italiano

Author

Jemmolo RM, Destro C, Burra P, Fagiuoli S, Cusinato R, Pontisso P, Angeli P Bruttocao A, Gerunda G, Maffei Faccioli A, Boccagni P, D’amico D, Naccarato R, Meloni GA, Crepaldi G., Jemmolo, R, Destro, C, Burra, P, Fagiuoli, S, Cusinato, R, Pontisso, P, Angeli, P, Gerunda, G, Maffei Faccioli, A, Boccagni, P, D’Amico, D, Naccarato, R, Meloni, G, and Crepaldi, G

Subjects
epatite da virus C trapianto di fegato
Published
1995

11. Recidiva di epatite da virus C dopo trapianto di fegato: Esperienza padovana

Author

Jemmolo RM, Burra P, Pontisso P, Fabris L, Strazzabosco M, Angeli P, Ruvoletto MG, Fagiuoli S, Gerunda GE, Tedesghi U, Crepaldi G, Jemmolo, R, Burra, P, Pontisso, P, Fabris, L, Strazzabosco, M, Angeli, P, Ruvoletto, M, Fagiuoli, S, Gerunda, G, Tedesghi, U, and Crepaldi, G

Subjects
Recidiva di epatite da virus C trapianto di fegato
Published
1994

14. The monoethylglycinexylidide test grading of liver cirrhosis

Author

Fabris, L, Jemmolo, R, Toffolo, G, Paleari, D, Viaggi, S, Rigon, M, Casagrande, F, Lirussi, F, Strazzabosco, M, Cobelli, C, Okolicsanyi, L, Jemmolo, RM, STRAZZABOSCO, MARIO, Okolicsanyi, L., Fabris, L, Jemmolo, R, Toffolo, G, Paleari, D, Viaggi, S, Rigon, M, Casagrande, F, Lirussi, F, Strazzabosco, M, Cobelli, C, Okolicsanyi, L, Jemmolo, RM, STRAZZABOSCO, MARIO, and Okolicsanyi, L.

Abstract

BACKGROUND: Monoethylglycinexylidide (MEGX) formation following lignocaine injection has recently been proposed as a simple dynamic liver function test based on a single measurement of its serum concentration. AIM: To determine the optimal sampling time for MEGX determination. METHODS: A modelling analysis of lignocaine and MEGX kinetics was performed in seven normals and in four patients with compensated liver cirrhosis; a similar study was performed in 74 cirrhotic patients, divided into two groups according to disease severity (Pugh score). RESULTS: Only the MEGX fractional formation rate (kf) and formation delay (tau) were significantly altered in cirrhotic patients compared to normals: kf = 0.15 +/- 0.03 vs. 0.32 +/- 0.10 min-1 (mean +/- s.d.); tau = 7.7 +/- 2.0 vs. 3.9 +/- 2.9 min-1. A good correlation was found between kf and late (r = 0.82) but not early (r = 0.63) serum MEGX formation, suggesting that late measurements for the clinical MEGX test are preferred. In the second part of our investigation, by discriminant analysis of MEGX test data for 74 cirrhotic patients, the late MEGX concentrations gave the best discrimination between the two classes. In particular, the 60 min MEGX concentration showed the best diagnostic accuracy (81%), sensitivity (75%) and specificity (84%). The association of this with other MEGX parameters, either singly or derived from the whole curve measurements, did not improve the performance of the method. CONCLUSION: The MEGX test, based on a single determination 60 min after lignocaine injection, may be regarded as a simple and sensitive quantitative liver function test

Published
1999

15. Qualità di vita del paziente con cirrosi: effetto del trapianto di fegato

Author

Burra, P, De Bona, M, Jemmolo, R, Boccagli, P, Tedeschi, U, Gerunda, G, Fagiuoli, S, Ruolo, G, Naccarato, R, Burra P, De Bona M, Jemmolo RM, Boccagli P, Tedeschi U, Gerunda G, Fagiuoli S, Ruolo GP, Naccarato R, Burra, P, De Bona, M, Jemmolo, R, Boccagli, P, Tedeschi, U, Gerunda, G, Fagiuoli, S, Ruolo, G, Naccarato, R, Burra P, De Bona M, Jemmolo RM, Boccagli P, Tedeschi U, Gerunda G, Fagiuoli S, Ruolo GP, and Naccarato R

Published
1997

16. ricorrenza di infezione da HCV e qualità di vita dopo trapianto di fegat

Author

De Bona, M, Burra, P, Ponton, P, Jemmolo, R, Destro, C, Boccagni, P, Buda, A, Targhetta, S, Fagiuoli, S, Rupolo, G, Naccarato, R, De Bona M, Burra P, Ponton P, Jemmolo RM, Destro C, Boccagni P, Buda A, Targhetta S, Fagiuoli S, Rupolo GP, Naccarato R, De Bona, M, Burra, P, Ponton, P, Jemmolo, R, Destro, C, Boccagni, P, Buda, A, Targhetta, S, Fagiuoli, S, Rupolo, G, Naccarato, R, De Bona M, Burra P, Ponton P, Jemmolo RM, Destro C, Boccagni P, Buda A, Targhetta S, Fagiuoli S, Rupolo GP, and Naccarato R

Published
1997

17. HBV-DNA sierico e tissutale in PCR in trapianto di fegato per malattie epatica HBV-correlata

Author

Targhetta, S, Burra, P, Pontisso, P, Jemmolo, R, Ruvoletto, M, Inturri, P, Fagiuoli, S, Zanus, G, Tedeschi, U, Naccarato, R, Targhetta S, Burra P, Pontisso P, Jemmolo RM, Ruvoletto MG, Inturri P, Fagiuoli S, Zanus G, Tedeschi U, Naccarato R, Targhetta, S, Burra, P, Pontisso, P, Jemmolo, R, Ruvoletto, M, Inturri, P, Fagiuoli, S, Zanus, G, Tedeschi, U, Naccarato, R, Targhetta S, Burra P, Pontisso P, Jemmolo RM, Ruvoletto MG, Inturri P, Fagiuoli S, Zanus G, Tedeschi U, and Naccarato R

Published
1995

18. Recidiva di epatite da virus C dopo trapianto di fegato: Esperienza di un centro Italiano

Author

Jemmolo, R, Destro, C, Burra, P, Fagiuoli, S, Cusinato, R, Pontisso, P, Angeli, P, Gerunda, G, Maffei Faccioli, A, Boccagni, P, D’Amico, D, Naccarato, R, Meloni, G, Crepaldi, G, Jemmolo RM, Destro C, Burra P, Fagiuoli S, Cusinato R, Pontisso P, Angeli P Bruttocao A, Gerunda G, Maffei Faccioli A, Boccagni P, D’amico D, Naccarato R, Meloni GA, Crepaldi G., Jemmolo, R, Destro, C, Burra, P, Fagiuoli, S, Cusinato, R, Pontisso, P, Angeli, P, Gerunda, G, Maffei Faccioli, A, Boccagni, P, D’Amico, D, Naccarato, R, Meloni, G, Crepaldi, G, Jemmolo RM, Destro C, Burra P, Fagiuoli S, Cusinato R, Pontisso P, Angeli P Bruttocao A, Gerunda G, Maffei Faccioli A, Boccagni P, D’amico D, Naccarato R, Meloni GA, and Crepaldi G.

Published
1995

19. Recidiva di epatite da virus C dopo trapianto di fegato: Esperienza padovana

Author

Jemmolo, R, Burra, P, Pontisso, P, Fabris, L, Strazzabosco, M, Angeli, P, Ruvoletto, M, Fagiuoli, S, Gerunda, G, Tedesghi, U, Crepaldi, G, Jemmolo RM, Burra P, Pontisso P, Fabris L, Strazzabosco M, Angeli P, Ruvoletto MG, Fagiuoli S, Gerunda GE, Tedesghi U, Crepaldi G, Jemmolo, R, Burra, P, Pontisso, P, Fabris, L, Strazzabosco, M, Angeli, P, Ruvoletto, M, Fagiuoli, S, Gerunda, G, Tedesghi, U, Crepaldi, G, Jemmolo RM, Burra P, Pontisso P, Fabris L, Strazzabosco M, Angeli P, Ruvoletto MG, Fagiuoli S, Gerunda GE, Tedesghi U, and Crepaldi G

Published
1994

20. The effect of drugs on bile flow and composition. An overview

Author

Okolicsanyi, L, Lirussi, F, Strazzabosco, M, Jemmolo, R, Orlando, R, Nassuato, G, Muraca, M, Crepaldi, G, STRAZZABOSCO, MARIO, Jemmolo, RM, Crepaldi, G., Okolicsanyi, L, Lirussi, F, Strazzabosco, M, Jemmolo, R, Orlando, R, Nassuato, G, Muraca, M, Crepaldi, G, STRAZZABOSCO, MARIO, Jemmolo, RM, and Crepaldi, G.

Abstract

Many drugs are eliminated via the hepatobiliary route, after biotransformation in the liver. Some of them may affect bile flow and/or the hepatic secretion of biliary lipids such as bile acids, cholesterol and phospholipids. Bile acids are the most potent agents which increase bile flow, especially unconjugated bile acids. Other drugs which increase bile flow include phenobarbitone (phenobarbital), theophylline, glucagon and insulin. In contrast, ethacrynic acid, amiloride, ouabain, oestrogens and chlorpromazine are among those agents which decrease bile flow. Biliary bile acid secretion is altered by a variety of drugs, including cheno- and ursodeoxycholic acids (CDCA and UCDA), the bile acid sequestrants cholestyramine and colestipol, and ethinyloestradiol. The composition of bile can also be altered by drug therapy. Thus, clofibrate increases biliary cholesterol secretion, and reduces bile acid concentrations, without altering biliary phospholipid concentrations. However, other clofibrate derivatives may produce changes of a different pattern, suggesting that the risk of developing gallstones may differ for each derivative. Nicotinic acid and d-thyroxine also increase biliary cholesterol saturation, while CDCA and UDCA reduce biliary cholesterol concentration. The potential consequences of drug-induced changes in bile flow and composition extend to the liver, the gallbladder and the intestine. If adverse effects are to be avoided, further study in this often overlooked area is required

Published
1986

21. Liver transplantation in Italy: Preliminary 10-year report

Author

Fagiuoli, S., Leandro, G., Bellati, G., Gasbarrini, A., Rapaccini, Gl, Pompili, M., Rendina, M., Denotariis, S., Francavilla, A., Gasbarrini, G., Ideo, G., Naccarato, R., Castagneto M, Agnes S., Paolo Angeli, Angelico, M., Ascione, A., Calise, F., Bertocchi, M., Dardano, G., Borzio, M., Budillon, G., Burra, F., FABIO FARINATI, Cadeo, Gp, Camisasca, M., Podda, M., Paolo, S., Cavallar, A., Mazziotti, A., Casciani, Cu, Tisone, G., Umberto Cillo, Damico, D., Colombo, M., Donato, F., Conoscitore, P., Coppolecchia, P., Dessanti, A., Fassati, Lr, Lucianetti, A., Rossi, G., Forti, D., Belli, L., Rondinara, Gf, Gaeta, G., Piccinino, F., Gerunda, G., Faccioli, Am, Gridelli, B., Guariso, Graziella, Zancan, L., Gullini, F., Boccia, S., Jemmolo, Rm, Marcellini, M., Marzano, Ma, Marzio, L., Mazzaferro, V., Regalia, E., Morelli, Mc, Pagliaro, L., Palazzo, U., Piras, Mr, Ricci, Gl, Salmi, A., Sama, C., Sangiovanni, A., Salizzoni, M., Marzano, A., Smedile, A., Rizzetto, M., Solinas, A., Spina, Gp, Stefanini, Gf, Andreone, P., Villa, E., and Zignego, L.

Subjects
liver transplantation, liver transplantation, liver disease, rejection, rejection, liver disease

23. The effect of drugs on bile flow and composition. An overview.

Author

Okolicsanyi L, Lirussi F, Strazzabosco M, Jemmolo RM, Orlando R, Nassuato G, Muraca M, and Crepaldi G

Subjects
Animals, Bile Acids and Salts metabolism, Cats, Chlorpromazine pharmacology, Cholesterol metabolism, Clofibrate pharmacology, Colchicine pharmacology, Cricetinae, Dehydrocholic Acid pharmacology, Diuretics pharmacology, Dogs, Enterohepatic Circulation drug effects, Estrogens pharmacology, Glucagon pharmacology, Guinea Pigs, Humans, Insulin pharmacology, Macaca mulatta, Phospholipids metabolism, Rabbits, Rats, Rifampin pharmacology, Rifamycins pharmacology, Somatostatin pharmacology, Theophylline pharmacology, Ursodeoxycholic Acid pharmacology, Bile metabolism, Cholagogues and Choleretics, Liver metabolism
Abstract

Many drugs are eliminated via the hepatobiliary route, after biotransformation in the liver. Some of them may affect bile flow and/or the hepatic secretion of biliary lipids such as bile acids, cholesterol and phospholipids. Bile acids are the most potent agents which increase bile flow, especially unconjugated bile acids. Other drugs which increase bile flow include phenobarbitone (phenobarbital), theophylline, glucagon and insulin. In contrast, ethacrynic acid, amiloride, ouabain, oestrogens and chlorpromazine are among those agents which decrease bile flow. Biliary bile acid secretion is altered by a variety of drugs, including cheno- and ursodeoxycholic acids (CDCA and UCDA), the bile acid sequestrants cholestyramine and colestipol, and ethinyloestradiol. The composition of bile can also be altered by drug therapy. Thus, clofibrate increases biliary cholesterol secretion, and reduces bile acid concentrations, without altering biliary phospholipid concentrations. However, other clofibrate derivatives may produce changes of a different pattern, suggesting that the risk of developing gallstones may differ for each derivative. Nicotinic acid and d-thyroxine also increase biliary cholesterol saturation, while CDCA and UDCA reduce biliary cholesterol concentration. The potential consequences of drug-induced changes in bile flow and composition extend to the liver, the gallbladder and the intestine. If adverse effects are to be avoided, further study in this often overlooked area is required.

Published
1986
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results